Skip to content

SLDE SLDE Restricted Cash Equivalents in Other Assets

Restricted Cash Equivalents in Other Assets at other companies

Agilon Health logo
Agilon HealthAGL
$71.58M+4,156%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$986K-32.0%
Ashland logo
AshlandASH
$276M+1.5%
Liberty Broadband Corporation logo
Liberty Broadband CorporationLBRDK
$57M-57.8%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$15.59M+703%
Trinet Group logo
Trinet GroupTNET
$122M-9.0%

Other financials

Income statement

See full
Revenue$389.3M+38.2%
Net income$139.5M+50.8%
EPS (diluted)$1.02+36.0%

Balance sheet

See full
Cash & equivalents$1.2B
Total debt$41.7M+378%
Total equity$1.1B
Total assets$2.9B

Cash flow

See full
Operating cash flow$289.5M+199%
CapEx$679.0K+15.5%
Free cash flow$288.8M+200%

Valuation

See full
Market cap$2.1B

Profitability

See full
Net margin38.9%+13.1pp
FCF margin78.1%

Returns & leverage

See full
Return on equity57.4%
Debt / equity

Where this comes from

Reported directly by SLDE in its filing.

Tagged under the XBRL concept us-gaap:RestrictedCashEquivalents.

The official record: SLDE’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about SLDE's restricted cash equivalents in other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SLDE's restricted cash equivalents in other assets?
SLDE (SLDE) reported restricted cash equivalents in other assets of $482.05M in Q1 2026.
What does restricted cash equivalents in other assets mean?
This captures cash and cash equivalents that are legally or contractually restricted from immediate use, typically held within non-current asset accounts. These funds are often set aside to satisfy regulatory requirements or specific collateral obligations related to insurance operations. Tracking this provides insight into the company's liquidity constraints and the portion of capital tied up for operational compliance.